Genmab
Manufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Kalvebod Brygge 43, København V, Capital...Phone Number
+45 70202728Website
www.genmab.comRevenue
$3.3 BillionStock Symbol
GMABIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
2
1
1
1
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and ToRead more
Genmab Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genmab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Genmab launches new products
Website visits: Recent activity has been detected on your website
Check out if Genmab is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Genmab has recently received funding, and reach out quickly before it becomes old news!
Click to see if Genmab had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Genmab
Funding: Get notified immidiatlly once Genmab has new funding data
Earning: See what the market has to say on Genmab recently announced quarterly report
Genmab, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Genmab as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Genmab is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genmab is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genmab.
Genmab Tech Stack
A closer look at the technologies used by Genmab
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Product Launch
Genmab has announced the European approval of TEPKINLY in combination with lenalidomide and rituximab for the treatment of follicular lymphoma in the second-line setting, making TEPKINLY the first and only bispecific-based therapy approved in Europe for this indication.
Product Launch
Product Launch
Genmab has reported rapid uptake of the chemo-free, fixed-duration EPKINLY plus R-squared regimen in the second-line follicular lymphoma setting, with over 90% of key customers ordering for two or more sites and increasing adoption from community practices.
Pharmaceuticals
Open Position
Open Position
Genmab News & Media
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in September 2026:Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genmab
Sign Up For FreeTo access detailed company insights
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody... Read More
